Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
暂无分享,去创建一个
J. Cervera | A. Hurtado | A. Jerez | E. Such | G. Sanz | M. Abáigar | M. Cabrero | K. Janusz | E. Lumbreras | C. Chillón | D. Valcárcel | M. Cañizo | M. Diez Campelo | J. H. Hernández Rivas | J. Caballero | M. Sánchez Barba | J. Hernández Sánchez | C. Calderón Cabrera | F. López Cadenas | Félix López Cadenas
[1] Michael Stadler,et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. , 2018, Blood.
[2] Yan-rong Liu,et al. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation , 2018, Annals of Hematology.
[3] J. Perkins,et al. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome , 2017, Clinical lymphoma, myeloma & leukemia.
[4] S. Miyano,et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.
[5] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[6] B. Wood,et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis , 2017, Haematologica.
[7] J. Cayuela,et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Bellazzi,et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Votavova,et al. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes , 2016, Oncotarget.
[10] J. Maciejewski,et al. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort , 2016, Leukemia.
[11] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[12] M. Konopleva,et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents , 2016, Oncotarget.
[13] S. Lee,et al. Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation , 2015, Bone Marrow Transplantation.
[14] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[15] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[17] A. Jankowska,et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms , 2014, Leukemia.
[18] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[19] M. Cazzola,et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Arenillas,et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations , 2013, British journal of haematology.
[21] E Mardis,et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes , 2013, Leukemia.
[22] M. Horowitz,et al. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] D. Neuberg,et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[25] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[26] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Mufti,et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Birnbaum,et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.
[29] J. Sierra,et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[31] B. Cho,et al. The Beneficial Effect of Chronic Graft-versus-Host Disease on the Clinical Outcome of Transplantation with Fludarabine/Busulfan-Based Reduced-Intensity Conditioning for Patients with De Novo Myelodysplastic Syndrome , 2007, International journal of hematology.
[32] J. Byrd,et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[33] J. Cigudosa,et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. , 2005, Haematologica.
[34] John P Klein,et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. , 2002, Blood.
[35] J. Sierra,et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. , 2002, Blood.
[36] H. Deeg,et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. , 2000, Blood.
[37] H. Kaneko,et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.